Statins and proteinuria

Current Atherosclerosis Reports

Volumn 7, Issue 5, 2005, Pages 351-357

  Vidt, Donald G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; COLESTYRAMINE; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALBUMIN BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENCY; ENZYME INHIBITION; FIBROGENESIS; FIBROSIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY SCAR; LONG TERM CARE; MICROALBUMINURIA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHORT COURSE THERAPY;

EID: 28044433218     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-005-0046-9     Document Type: Review

References (50)

1. Oliver J, MacDowell M, Lee YC: Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria; tubular absorption, droplet formation, and the disposal of proteins. J Exp Med 1954, 99:589-604.
2. Straus W. Cytochemical investigation of phagosomes and related structures in cryostat sections of the kidney and liver of rats after Intravenous administration of horseradish peroxidase. Exp Cell Res 1962, 27:80-94.
3. Novikoff AB: The rat kidney; cytochemical and electron microscopic studies. In Ciba Foundation Symposium. Edited by Quinn EL, Kass EK. Boston: Little, Brown; 1960: 113-144.
4. Christensen EI, Nielsen S: Structural and functional features of protein handling in the kidney proximal tubule. Semin Nephrol 1991, 11:414-439.
5. Maack T: Renal filtration, transport and metabolism of protein. In The Kidney, edn 3. Edited by Seldin DW, Giebish G. Philadelphia: Lippincott, Williams & Wilkins; 2000: 2235-2267.
6. Clague MJ: Molecular aspects of the endocytic pathway. Biochem J 1998, 336(Pt 2):271-282.
7. Wall DA, Maack T. Endocytic uptake, transport, and catabolism of proteins by epithelial cells. Am J Physiol 1985, 248:C12-C20.
8. Christensen EI, Birn H: Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001, 280:F562-F573.
9. Christensen EI, Birn H, Verroust P, Moestrup SK: Membrane receptors for endocytosis in the renal proximal tubule. Int Rev Cytol 1998, 180:237-284.
10. Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 2004, 15:2502-2503.
11. Brunskill NJ, Cockcroft N, Nahorski S, Walls J: Albumin endocytosis is regulated by heterotrimeric GTP-binding protein G alpha i-3 in opossum kidney cells. Am J Physiol 1996, 271:F356-F364.
12. Leheste JR, Rolinski B, Vorum H, et al.: Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999, 155:1361-1370.
13. Vidt DG, Cressman MD, Harris S, et al.: Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004, 102:52-60.
14. Schwegler JS, Heppelmann B, Mildenberger S, Silbernagl S: Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: a model for proximal tubular protein reabsorption. Pflugers Arch 1991, 418:383-392.
15. Sidaway JE, Davidson RG, McTaggart F, et al.: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004, 15:2258-2265.
16. Verhulst A, D'Haese PC, De Broe ME: Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004, 15:2249-2257.
17. Singhvi SM, Pan HY, Morrison RA, Willard DA: Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990, 29:239-243.
18. Martin PD, Warwick MJ, Dane AL, et al.: Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003, 25:2553-2563.
19. Endocrinologic and Metabolic Drugs Advisory Committee, July 9 2003. Food and Drug Administration Center for Drug Evaluation and Research. Department of Health and Human Services. 2003. Available at http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3968T1.doc. Accessed July 5, 2004.
20. Pharmacology/Toxicology. NDA 21-366 Crestor July 9, 2003. Advisory Committee Briefing Document. Department of Health and Human Services. 2004. Available at http://www.fda.gov.ohrms/dockets/ac/03/briefing/ 3968B102-FDA-PharmTox%20Review.pdf. Accessed on July 5, 2004.
21. Tonelli M, Moye L, Sacks FM, et al.: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003, 138:98-104.
22. Heart Protection Study Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
23. Collins R, Armitage J, Parish S, et al., for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
24. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation GREACE. study. J Clin Pathol 2004, 57:728-734.
25. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 2002, 136:604-615.
26. Zoja C, Donadelli I, Colleoni S, et al.: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998, 53:1608-1615.
27. Orisio S, Benigni A, Bruzzi I, et al.: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993, 43:354-358.
28. Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995, 47:1546-1557.
29. Remuzzi G: Nephropathic nature of proteinuria. Curr Opin Nephrol Hypertens 1999, 8:655-663.
30. Comper WD, Osicka TM: Albumin-like material in urine. Kidney Int Suppl 2004, S65-S66.
31. Eppel GA, Osicka TM, Pratt LM, et al.: The return of glomerular filtered albumin to the rat renal vein - the albumin retrieval pathway. Renal Fail 2001, 23:347-363.
32. Wharram BL, Goyal M, Gillespie PJ, et al.: Altered podocyte structure in GLEPP1 Ptpro.-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 2000, 106:1281-1290.
33. Hara M, Yanagihara T, Takada T, et al.: Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998, 18:35-41.
34. Nakamura T, Ushiyama C, Suzuki S, et al.: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379-1383.
35. Kriz W, LeHir M: Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005, 67:404-419.
36. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799-812.
37. Brouhard BH, Takamori H, Satoh S, et al.: The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 1994, 8:436-440.
38. Inman SR, Stowe NT, Cressman MD, et al.: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999, 317:215-221.
39. Liang K, Vaziri ND: HMG-CoA reductase inhibition with rosuvastatin improves hyperlipidemia and proteinuria and reverses LDL receptor and HDL receptor deficiencies in the nephrotic syndrome [abstract]. J Am Soc Nephrol 2003, 14:168A.
40. Usui H, Shikata K, Matsuda M, et al.: HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003, 18:265-272.
41. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001, 59:260-269.
42. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003, 41:565-570.
43. Lee TM, Su SF, Tsai CH: Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002, 40:67-73.
44. Tonolo G, Melis MG, Formato M, et al.: Additive effects of sinivastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000, 30:980-987.
45. Perkins BA, Ficociello LH, Silva KH, et al.: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285-2293.
46. Adam A, Raij L: Nitric oxide - angiotensin II axis in renal and cardiovascular injury. J Nephrol 2000, 13:211-220.
47. Kurose I, Wolf R, Grisham MB, Granger DN: Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 1994, 74:376-382.
48. Tesfamariam B, Frohlich BH, Gregg RE: Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999, 34:95-101.
49. Sposito AC, Mansur AP, Coelho OR, et al.: Additional reduction in blood pressure after cholesterol-lowering treatment by statins lovastatin or pravastatin. in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors enalapril or lisinopril. Am J Cardiol 1999, 83:1497-1499.
50. Ikeda T, Sakurai J, Nakayama D, et al.: Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004, 17:502-506.